Catecholamines in hypertension.
D000818:Animals; D002395:Catecholamines / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005730:Ganglionic Blockers / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000378:metabolism*; D008781:Methyltyrosines / Q000627:therapeutic use; D009411:Nerve Endings / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010673:Pheochromocytoma / Q000188:drug therapy / Q000503:physiopathology; D013564:Sympathetic Nervous System / Q000502:physiology; D013578:Synephrine / Q000627:therapeutic use
D002395:Catecholamines; D005730:Ganglionic Blockers; D008781:Methyltyrosines; D010643:Phenoxybenzamine; D013578:Synephrine; D009638:Norepinephrine; D010646:Phentolamine